Pierre Marc Bélichard
Founder chez Enterome SA
Profil
Pierre Marc Bélichard is the founder of Fovea Pharmaceuticals SA (founded in 2005), Enterome SA (founded in 2012), and Maat Pharma SA (founded in 2014).
He held the position of Chief Operating Officer at Fovea Pharmaceuticals SA from 2009 to 2011.
He is the Chief Executive Officer & Director at Enterome SA from 2012 to present.
He was a Non-Executive Director at Maat Pharma SA. Currently, he is a Director at Polaris SA since 2011 and a Director at ILTOO Pharma SAS.
In the past, he was the Chairman at Microbiome Diagnostics Partners SA. He held the position of Head-Business Development at Fournier Pharma SA from 1993 to 2000.
He was the Head-European Commercial Operations at Ethypharm SAS.
He was the Vice President-Business Development at Urogene SA and Vice President-Business Development Ophthalmology at Sanofi-Aventis France SA.
Postes actifs de Pierre Marc Bélichard
| Sociétés | Poste | Début |
|---|---|---|
Polaris SA /FR/
 Polaris SA /FR/ Pharmaceuticals: MajorHealth Technology Polaris SA engages in the biotechnology industry and specializes in the field of healthy omega 3 lipids. The company was founded by St?phane Lozachmeur and Gildas Breton on July 1, 1994 and is headquartered in Quimper, France. | Director/Board Member | 30/07/2011 |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Founder | 01/01/2012 |
ILTOO Pharma SAS
 ILTOO Pharma SAS Miscellaneous Commercial ServicesCommercial Services ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively. | Director/Board Member | - |
Anciens postes connus de Pierre Marc Bélichard
| Sociétés | Poste | Fin |
|---|---|---|
Fournier Pharma SA
 Fournier Pharma SA Pharmaceuticals: MajorHealth Technology Fournier Pharma SA manufactures pharmaceutical products. The firm is also in the engaged in the research, development, production and marketing of molecules. The company has operations in Canada, China, Algeria, Bulgaria, Thailand and Turkey. It was founded in 1880 and is headquartered in Chenôve, France. | Corporate Officer/Principal | 01/01/2000 |
Microbiome Diagnostics Partners SA
 Microbiome Diagnostics Partners SA BiotechnologyHealth Technology Microbiome Diagnostics Partners SA develops and commercializes microbiome-based diagnostics. The company was founded on August 8, 2017 and is headquartered in Epalinges, Switzerland. | Chairman | - |
| MAAT PHARMA | Founder | - |
Sanofi-Aventis France SA
 Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Corporate Officer/Principal | - |
Ethypharm SAS
 Ethypharm SAS Pharmaceuticals: MajorHealth Technology Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MAAT PHARMA | Health Technology |
| Entreprise privées | 9 |
|---|---|
Fournier Pharma SA
Fournier Pharma SA Pharmaceuticals: MajorHealth Technology Fournier Pharma SA manufactures pharmaceutical products. The firm is also in the engaged in the research, development, production and marketing of molecules. The company has operations in Canada, China, Algeria, Bulgaria, Thailand and Turkey. It was founded in 1880 and is headquartered in Chenôve, France. | Health Technology |
Ethypharm SAS
Ethypharm SAS Pharmaceuticals: MajorHealth Technology Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France. | Health Technology |
Urogene SA
 Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Polaris SA /FR/
Polaris SA /FR/ Pharmaceuticals: MajorHealth Technology Polaris SA engages in the biotechnology industry and specializes in the field of healthy omega 3 lipids. The company was founded by St?phane Lozachmeur and Gildas Breton on July 1, 1994 and is headquartered in Quimper, France. | Health Technology |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Health Technology |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Sanofi-Aventis France engages in wholesale of pharmaceutical products. The company is headquartered in Gentilly, France. | Distribution Services |
ILTOO Pharma SAS
ILTOO Pharma SAS Miscellaneous Commercial ServicesCommercial Services ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively. | Commercial Services |
Microbiome Diagnostics Partners SA
Microbiome Diagnostics Partners SA BiotechnologyHealth Technology Microbiome Diagnostics Partners SA develops and commercializes microbiome-based diagnostics. The company was founded on August 8, 2017 and is headquartered in Epalinges, Switzerland. | Health Technology |
